DYNAPEN Drug Patent Profile

« Back to Dashboard

Which patents cover Dynapen, and what generic alternatives are available?

Dynapen is a drug marketed by Apothecon and is included in one NDA.

The generic ingredient in DYNAPEN is dicloxacillin sodium. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the dicloxacillin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dynapen

A generic version of DYNAPEN was approved as dicloxacillin sodium by CHARTWELL RX on June 3^rd, 1982.

Summary for DYNAPEN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	30
Patent Applications:	4,967
DailyMed Link:	DYNAPEN at DailyMed

US Patents and Regulatory Information for DYNAPEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	DYNAPEN	dicloxacillin sodium	FOR SUSPENSION;ORAL	050337-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Dynapen Market Dynamics, Patent Status, FDA History, and Financial Trajectory

Last updated: October 9, 2026

Dynapen is the former U.S. brand for dicloxacillin sodium, an oral, penicillinase-resistant penicillin used for susceptible staphylococcal infections. Its commercial value is now limited. The product has no meaningful branded exclusivity, faces generic competition, and is not reported as a standalone revenue line by its historical manufacturer. Current economics are driven by low-cost generic dicloxacillin, limited clinical demand, supply availability, and the broader contraction of the oral anti-staphylococcal antibiotic market.

What is Dynapen and who manufactured it?

Dynapen is a capsule formulation of dicloxacillin sodium, a beta-lactam antibiotic in the penicillin class. Dicloxacillin is resistant to degradation by many staphylococcal beta-lactamases and historically was used for infections caused by methicillin-susceptible Staphylococcus aureus, or MSSA.

Attribute	Dynapen
Active ingredient	Dicloxacillin sodium
Drug class	Penicillinase-resistant penicillin
Dosage form	Oral capsules
Historical strengths	125 mg, 250 mg, 500 mg
Primary indication	Infections caused by susceptible gram-positive organisms
Historical sponsor	Bristol-Myers Squibb
U.S. regulatory status	Legacy approved product; branded commercial relevance is minimal
Current market structure	Generic-dominated
Biosimilar exposure	None

The product label recommends administration on an empty stomach because food can reduce absorption. The label also identifies hypersensitivity reactions, gastrointestinal effects, and antibiotic-associated colitis as key safety considerations. Dicloxacillin is generally reserved for infections where a narrow-spectrum anti-staphylococcal penicillin is clinically appropriate rather than used as a broad empiric antibiotic.[1]

What is the FDA regulatory status of Dynapen?

Dynapen is a legacy small-molecule antibiotic rather than a newly marketed branded product. The FDA has historically listed dicloxacillin products through abbreviated and legacy application pathways. Generic dicloxacillin sodium capsules remain the relevant U.S. product category.

The FDA’s Orange Book distinguishes between products that are discontinued for commercial reasons and products withdrawn from sale for safety or efficacy concerns. Dynapen’s commercial decline should not be interpreted as a safety withdrawal without a specific FDA determination. The principal market event is loss of commercial relevance and substitution by generic products.

What is the Orange Book status of Dynapen?

The Orange Book framework is relevant because generic dicloxacillin applicants can rely on the reference product’s established safety and efficacy record through the abbreviated new drug application pathway. Dynapen has no known modern period of branded market exclusivity comparable to products approved under the Hatch-Waxman framework in recent decades.

For practical market analysis:

• Dynapen has no active branded pricing power.
• Generic dicloxacillin is the commercially relevant product.
• No current Dynapen patent barrier is generally recognized as preventing generic substitution.
• Any historical patents associated with the original product would have expired long ago.
• Product availability depends more on manufacturer economics and distribution than on patent protection.

When did Dynapen lose exclusivity?

Dynapen’s core exclusivity expired decades ago. Dicloxacillin was introduced before the modern commercial importance of Orange Book patent listings and before current pharmaceutical lifecycle-management practices became standard.

Exclusivity category	Dynapen assessment
New chemical entity exclusivity	Expired
Original composition-of-matter patent	Expired
Pediatric exclusivity	No current relevance
Orphan exclusivity	Not applicable
U.S. formulation exclusivity	Expired or commercially irrelevant
Active Orange Book patent barrier	None generally recognized
Generic substitution	Available in principle, subject to state and pharmacy rules

The key commercial distinction is between legal availability and actual supply. Generic dicloxacillin may be approved yet intermittently unavailable if manufacturers exit the market, reduce production, or encounter active-pharmaceutical-ingredient constraints.

What patents protect Dynapen and dicloxacillin?

No active patent estate is generally associated with the original Dynapen brand. Dicloxacillin is an old small molecule, and its core chemical protection expired many years ago.

Patent categories relevant to dicloxacillin

Patent category	Current commercial impact
Active ingredient	None expected; expired
Salt form	No meaningful current barrier expected
Capsule formulation	No active branded barrier generally recognized
Method of treatment	Historical claims, if any, would not normally block routine generic sales
Manufacturing process	Potentially relevant only if a manufacturer claims a narrow process, but unlikely to support Dynapen pricing
Device or delivery technology	Not applicable to conventional capsules

A generic manufacturer could still face ordinary regulatory and manufacturing requirements. Those requirements are not equivalent to patent exclusivity. Dicloxacillin’s low unit value makes costly patent litigation economically unattractive in most circumstances.

Have generic companies challenged Dynapen patents under Paragraph IV?

There is no prominent recent Paragraph IV litigation campaign associated with Dynapen. The reason is economic: the product is an old generic antibiotic with limited market value and no meaningful branded patent wall.

Under Hatch-Waxman, a Paragraph IV certification challenges the validity, enforceability, or infringement of a listed patent. That process is most commercially relevant when a brand product has substantial sales and a generic launch could produce a significant revenue transfer. Dynapen does not fit that profile.

Generic entry risk

Generic entry risk is effectively realized rather than prospective. The product category is already genericized.

Risk factor	Assessment
Patent litigation risk	Low
Regulatory filing risk	Low to moderate
Manufacturing disruption risk	Moderate
Price erosion risk	High
Brand replacement risk	Complete or near-complete
Generic consolidation risk	Moderate to high
Shortage risk	More relevant than patent risk

The main threat to market continuity is not a generic launch. It is a reduction in the number of active suppliers.

What is the current market for dicloxacillin?

Dicloxacillin occupies a narrow segment of the oral antibiotic market. Clinicians may choose it for confirmed or strongly suspected MSSA infections when a narrow-spectrum oral penicillin is suitable. Cephalexin, clindamycin, amoxicillin-clavulanate, and other agents often compete for the same prescribing occasions depending on the organism, infection site, allergy history, local resistance patterns, and treatment guidelines.

Competitive landscape

Product or class	Competitive relationship with dicloxacillin
Cephalexin	Common oral alternative for susceptible staphylococcal and streptococcal infections
Clindamycin	Alternative when beta-lactams cannot be used, but with higher concern for C. difficile infection
Amoxicillin-clavulanate	Broader-spectrum alternative for mixed or polymicrobial infections
Flucloxacillin	Important international comparator; not broadly marketed in the United States
Nafcillin or oxacillin	Intravenous alternatives for more serious MSSA infections
Trimethoprim-sulfamethoxazole	Used in selected staphylococcal infections, particularly where MRSA is a concern
Doxycycline	Alternative in certain community-acquired staphylococcal infections

Dicloxacillin’s clinical positioning is constrained by the prevalence of community-associated MRSA, which is resistant to dicloxacillin and other beta-lactam antibiotics. It remains relevant for MSSA, but microbiological confirmation and local prescribing practice determine demand.

How strong is the Dynapen patent estate?

The Dynapen patent estate is commercially weak because the core product is old, genericized, and no longer protected by a meaningful period of market exclusivity.

Patent-strength assessment

Criterion	Rating	Rationale
Composition-of-matter protection	0/5	Historical protection expired
Formulation protection	0/5	Conventional capsule formulation
Method-of-use protection	0/5	No commercially meaningful active barrier identified
Manufacturing protection	1/5	Possible process know-how, but limited blocking value
Regulatory exclusivity	0/5	No current branded exclusivity
Litigation leverage	0/5	Low-value product and no recognized active patent wall
Overall estate strength	0/5	No meaningful current patent moat

The relevant intellectual property may consist of manufacturing know-how, supplier relationships, quality systems, and regulatory files. Those assets can support operational advantage but do not provide the exclusionary rights associated with an active patent portfolio.

What formulations are protected by Dynapen?

Dynapen was marketed as an immediate-release oral capsule. There is no commercially significant extended-release, injectable, depot, inhaled, or device-based formulation associated with the brand.

The conventional capsule format creates limited differentiation. Generic manufacturers can usually produce an equivalent dosage form without developing complex delivery technology. This reduces development risk but also limits pricing power.

Formulation-related barriers could arise from:

• Capsule manufacturing scale.
• Stability and dissolution controls.
• API sourcing.
• Bioequivalence documentation.
• Packaging and serialization compliance.
• Quality-system requirements.

These are operational barriers, not durable patent barriers.

What is the financial trajectory for Dynapen?

Dynapen’s standalone financial trajectory is best characterized as a decline from branded sales to generic substitution, followed by low-value or discontinued branded activity. Public company filings do not generally disclose Dynapen revenue separately, preventing a reliable product-level revenue series.

Period	Financial trajectory
Historical branded period	Revenue supported by brand recognition and limited competition
Genericization period	Rapid price and volume pressure after generic availability
Mature generic period	Low prices, fragmented supply, minimal brand contribution
Current commercial position	No meaningful standalone branded growth thesis

The product’s economics are structurally weak for several reasons:

1. Dicloxacillin is inexpensive to manufacture relative to many specialty medicines.
2. The addressable patient population is narrow.
3. Physicians have several substitute antibiotics.
4. Generic substitution removes branded price premiums.
5. Antibiotic stewardship limits unnecessary prescribing.
6. A shortage or supplier exit can reduce volume without improving long-term franchise value.

Revenue exposure

Dynapen should not be treated as a material revenue driver for its historical sponsor unless a company-specific filing identifies a continuing product contribution. Bristol-Myers Squibb’s modern financial disclosures focus on major commercial products and therapeutic franchises, not legacy dicloxacillin brands.[2]

For investors and licensing teams, the relevant conclusion is that Dynapen has negligible identifiable revenue exposure compared with major branded antibiotics, oncology products, immunology medicines, or cardiovascular franchises.

Which companies are challenging Dynapen commercially?

The principal commercial challengers are generic dicloxacillin manufacturers and substitute antibiotic suppliers rather than branded patent challengers.

Competition can come from:

• Generic dicloxacillin manufacturers.
• Contract manufacturers supplying low-volume antibiotics.
• Manufacturers of cephalexin and other oral beta-lactams.
• Suppliers of clindamycin, doxycycline, and trimethoprim-sulfamethoxazole.
• Hospital and retail pharmacy purchasing groups.

Because product-level supplier participation changes over time, a static competitor list can quickly become outdated. The durable competitive fact is that dicloxacillin is a low-margin, genericized product category with limited room for premium pricing.

What generic launch scenarios exist for Dynapen?

A conventional generic launch scenario has already occurred. Future market scenarios are primarily supply-based.

Scenario 1: Stable generic supply

Multiple suppliers remain active. Prices stay low, pharmacies substitute generic dicloxacillin, and Dynapen has no material commercial recovery.

Scenario 2: Supplier contraction

One or more manufacturers exit because of low margins. Wholesale acquisition prices may rise temporarily, but the brand is unlikely to regain durable value unless a company relaunches it with reliable supply and distribution.

Scenario 3: Shortage-driven opportunity

A manufacturer acquires or reintroduces the product during a shortage. The opportunity would depend on FDA approval status, manufacturing readiness, API availability, and reimbursement. Any pricing improvement would likely be limited by payer controls and substitution.

Scenario 4: Clinical displacement

Greater use of cephalexin, clindamycin, or other agents reduces dicloxacillin demand. This is the most likely long-term pressure because it arises from prescribing preference rather than patent events.

What patent litigation or settlement agreements affect Dynapen?

No major current patent litigation or settlement agreement is broadly associated with Dynapen. A settlement would have limited commercial significance without an active patent estate or a substantial branded market.

The absence of litigation is itself informative. It indicates that the product does not present the standard profile of a high-value branded medicine facing an imminent generic challenge. There is no apparent litigation-driven launch date, 180-day exclusivity event, or settlement-restricted generic entry date shaping the market.

Does Dynapen face biosimilar risk?

No. Biosimilars apply to biologic products. Dynapen contains dicloxacillin sodium, a chemically synthesized small molecule. The relevant competitive pathway is generic substitution under the ANDA system, not the biosimilar pathway under the Public Health Service Act.

How does Dynapen compare with other legacy antibiotics?

Factor	Dynapen/dicloxacillin	Cephalexin	Clindamycin	Amoxicillin-clavulanate
Core use	MSSA and susceptible gram-positive infections	Broad oral gram-positive coverage	Selected gram-positive and anaerobic infections	Broader mixed infections
MRSA activity	No	No	Variable, resistance-dependent	No
Generic status	Mature	Mature	Mature	Mature
Brand pricing power	None	None	None	None
Clinical differentiation	Narrow-spectrum anti-staphylococcal use	Familiar, widely used oral option	Allergy and anaerobic coverage	Broad-spectrum coverage
Commercial growth potential	Very low	Low	Low	Low to moderate in selected markets
Supply-chain importance	Moderate for a niche product	Higher due to broader use	Moderate	Higher due to broader use

Dicloxacillin’s narrow spectrum can be clinically useful, but that same narrow positioning limits its volume and commercial upside.

What geographic markets remain relevant?

Dynapen is principally a U.S. legacy brand issue. Dicloxacillin and related anti-staphylococcal penicillins have different commercial positions outside the United States. In several markets, flucloxacillin is more prominent than dicloxacillin, while other countries rely more heavily on cephalexin or anti-staphylococcal injectable products.

Geographic value is therefore uneven:

• United States: mature generic market with limited brand relevance.
• United Kingdom and parts of Europe: flucloxacillin is often the more relevant oral anti-staphylococcal penicillin.
• Canada and selected other markets: dicloxacillin may remain available, but branding and supplier participation vary.
• Emerging markets: access depends on local registration, procurement, and antibiotic policy.

Cross-border licensing value is low unless tied to a broader anti-infective portfolio, manufacturing platform, or hospital procurement contract.

Key Takeaways

• Dynapen is the legacy brand for dicloxacillin sodium capsules.
• Its composition, formulation, and regulatory exclusivity have expired or have no current commercial relevance.
• There is no meaningful active Dynapen patent estate or major Paragraph IV litigation profile.
• Generic dicloxacillin is the relevant U.S. market product.
• The principal commercial risks are low pricing, limited demand, supplier exit, and clinical substitution.
• Standalone Dynapen revenue is not publicly reported and should not be treated as material to the historical sponsor’s current financial profile.
• Dynapen has no biosimilar exposure because dicloxacillin is a small-molecule antibiotic.
• Any future value would come from reliable generic supply, shortage management, or portfolio bundling rather than patent exclusivity.

FAQs About Dynapen and Dicloxacillin

Is Dynapen still available in the United States?

The branded product has limited or no practical commercial significance. Generic dicloxacillin sodium capsules are the relevant source, subject to manufacturer and pharmacy availability.

Is dicloxacillin the same as penicillin?

Dicloxacillin is a penicillin-class antibiotic, but it is designed to resist many staphylococcal beta-lactamases. It is more narrowly targeted than broad-spectrum penicillin combinations.

Does Dynapen have an active Orange Book patent?

No meaningful active patent barrier is generally associated with the legacy Dynapen brand. The product is treated as a mature genericized medicine.

Can a company relaunch Dynapen profitably?

A relaunch could address a supply gap, but durable profitability would be difficult without a shortage, institutional contract, differentiated packaging, or a broader antibiotic portfolio. Patent-based pricing power is unavailable.

Is dicloxacillin still used for MRSA?

No. MRSA is resistant to dicloxacillin by definition. Dicloxacillin is used for susceptible organisms, particularly MSSA, when clinical and microbiological factors support its use.

References

1. U.S. Food and Drug Administration. (n.d.). Dynapen (dicloxacillin sodium) capsule prescribing information. FDA Drugs@FDA and product labeling records.

2. Bristol-Myers Squibb Company. (Various years). Annual reports and Form 10-K filings. U.S. Securities and Exchange Commission.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. National Library of Medicine. (n.d.). Dicloxacillin sodium capsule drug labeling. DailyMed.

5. U.S. Food and Drug Administration. (2016). Abbreviated new drug application process and generic drug standards. FDA.